# Evaluation of Blood/Imaging Based Biomarkers, Aromatase Inhibitor Induced Musculoskeletal Syndrome

> **NCT03665077** · NA · COMPLETED · sponsor: **University of Arizona** · enrollment: 28 (actual)

## Conditions studied

- Aromatase Inhibitor Induced Musculoskeletal Syndrome (AIMSS)
- Breast Cancer

## Interventions

- **DIAGNOSTIC_TEST:** Initial blood draw
- **DIAGNOSTIC_TEST:** Initial SWE ultrasound
- **DIAGNOSTIC_TEST:** Blood draw at three months
- **DIAGNOSTIC_TEST:** Blood draw at six months
- **DIAGNOSTIC_TEST:** SWE ultrasound at six months

## Key facts

- **NCT ID:** NCT03665077
- **Lead sponsor:** University of Arizona
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-28
- **Primary completion:** 2022-06-15
- **Final completion:** 2022-06-15
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2023-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03665077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03665077, "Evaluation of Blood/Imaging Based Biomarkers, Aromatase Inhibitor Induced Musculoskeletal Syndrome". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03665077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*